The understanding of lysosomes has come a long way since the initial discovery of their role
in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle …

The etiology of idiopathic Parkinson's disease (iPD) is multifactorial, and both genetics and
environmental exposures are risk factors. While mutations in leucine-rich repeat kinase-2 …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors
for Parkinson's disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal …

Background Leucine‐rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic
approach for the treatment of Parkinson's disease (PD). Objective The aim of this study was …

Extracellular vesicles (EVs) are a subclass of biological nanoparticles secreted by most cell
types. Once secreted, EVs can travel long distances to deliver their content to target cells …

Background Pathogenic leucine‐rich repeat kinase 2 LRRK2 mutations may increase
LRRK2 kinase activity and Rab substrate phosphorylation. Genetic association studies link …

Background LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced
to clinical trials in idiopathic Parkinson's disease (iPD). LRRK2 phosphorylates Rab10 on …

Missense mutations in the LRRK2 gene were first identified as a pathogenic cause of
Parkinson's disease (PD) in 2004. Soon thereafter, a founder mutation in LRRK2, p. G2019S …

Parkinson´ s disease (PD) is a common neurodegenerative movement disorder and leucine-
rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention …

Mutations in Leucine-rich repeat kinase 2 (LRRK2) are a risk factor for and a cause of
sporadic and familial Parkinson's disease (PD), respectively. These mutations are some of …